

Peptide Therapeutics Forum

Congress Center Basel, 10 - 11 September 2019

Chairs

Thomas Vorherr (Novartis Pharma AG, Basel, Switzerland)

Roderich Süßmuth (Technical University of Berlin, Germany)

Tuesday, 10 September 2019

- 10.00 **Playmolecule, a repository of deep learning based applications for biomolecule design**
Franck Chevalier (Acellera, Barcelona, Spain)
- 10.30 **Optimization of the lipopeptide arylomycin natural product into Gram-negative antibiotics**
Christopher Heise (Genentech Research & Early Development, San Francisco, United States)
- 11.00** *Break*
- 11.30 **Activation of the Hippo pathway via targeting of transcription factor TEAD using designed tertiary protein structure mimetics**
Helene Adihou (Astra Zeneca, Dortmund, Germany)
- 12.00 **Elimination of A β oligomers by the orally available all-D-peptide PRI-002 reverses cognition deficits and decelerates neurodegeneration**
Dieter Willbold (University of Düsseldorf, Germany)
- 12.30** *Lunch break and Industry Symposium*
- 14.00 **PLENARY LECTURE**
The chemical evolution of endocrine hormones
Richard DiMarchi (University of Indiana, Bloomington, United States)
- 15.00** *Break*
- 15.30 **Peptide platforms for therapy and imaging: The first total synthesis of amanitin for ADCs and one-step 18F-labeling PET-oncology**
David Perrin (University of British Columbia, Vancouver, Canada)
- 16.00 **Virobiome derived anti-inflammatory short peptides**
Michael Ruff (Creative BioPeptides)

Wednesday, 11 September 2019

- 10.00 **Exotic side chain-to-side-chain cyclization modes in octreotide analogs for tumor pretargeting**
Anna Maria Papini (University of Florence, Italy)
- 10.30 **Peptide-based radiopharmaceuticals for cancer imaging and therapy
Agonist or Antagonist? Does it really matter?**
Melpomeni Fani (University Hospital Basel, Switzerland)
- 11.00 Break**
- 11.30 **Vancomycin regains effectiveness for resistant bacteria by conjugation to cationic peptides**
Walter Mier (University of Heidelberg, Germany)
- 12.00 **Peptide discovery at protagonist therapeutics: A platform yielding multiple clinical candidates**
Mark Smythe (Protagonist, Newark, United States)
- 12.30 Lunch break and Industry Symposium**
- 14.00 **Disulfide-rich peptide production**
Mike Pennington (AmbioPharm, North Augusta, United States)
- 14.30 **A new green solvent for solid phase peptide synthesis**
Jon Collins (CEM, Matthews, United States)
- 15.00 Break**
- 15.30 **Synthetic immune system engagers target cancer cells and prevent tumor formation**
Christian Becker (University of Vienna, Austria)
- 16.00 **Discovery and clinical development of an inhaled cyclic peptide elastase inhibitor for the treatment of cystic fibrosis**
Roxana Drake & Marc Thommen (Santhera Pharmaceuticals CH Ltd., Pratteln, Switzerland)

The programme indicated maybe subject to change!